Literature DB >> 23099120

In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a).

Michael E Frischmann1, Katsunori Ikewaki, Evi Trenkwalder, Claudia Lamina, Benjamin Dieplinger, Muhidien Soufi, Horst Schweer, Juergen R Schaefer, Paul König, Florian Kronenberg, Hans Dieplinger.   

Abstract

OBJECTIVE: Lipoprotein(a) [Lp(a)] consists of apolipoprotein B-100 (apoB-100) as part of an LDL-like particle and the covalently linked glycoprotein apolipoprotein(a) [apo(a)]. Detailed mechanisms of its biosynthesis, assembly, secretion and catabolism are still poorly understood. To address the Lp(a) assembly mechanism, we studied the in vivo kinetics of apo(a) and apoB-100 from Lp(a) and LDL apoB-100 in nine healthy probands using stable-isotope methodology.
METHODS: The level of isotope enrichment was used to calculate the fractional synthesis rate (FSR), production rate (PR) and retention time (RT) using SAAMII software and multicompartmental modeling.
RESULTS: We observed a similar mean PR for apo(a) (1.15 nmol/kg/d) and apoB-100 (1.31 nmol/kg/d) from Lp(a), which differed significantly from the PR for apoB-100 from LDL (32.6 nmol/kg/d). Accordingly, mean FSR and RT values for Lp(a)-apo(a) were similar to those of Lp(a)-apoB and different from those for LDL-apoB.
CONCLUSION: Two different kinetic apoB pools within Lp(a) and LDL suggest intracellular Lp(a) assembly from apo(a) and newly synthesized LDL.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099120     DOI: 10.1016/j.atherosclerosis.2012.09.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  21 in total

Review 1.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

2.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

Review 3.  In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease.

Authors:  Katsunori Ikewaki
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

4.  Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins.

Authors:  Michael E Lassman; Thomas McAvoy; Anita Y H Lee; Derek Chappell; Oitak Wong; Haihong Zhou; Gissette Reyes-Soffer; Henry N Ginsberg; John S Millar; Daniel J Rader; David E Gutstein; Omar Laterza
Journal:  Clin Chem       Date:  2014-04-21       Impact factor: 8.327

Review 5.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

6.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

Review 7.  Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Authors:  Michael B Boffa
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

8.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

9.  Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.

Authors:  Mikaël Croyal; Fanta Fall; Véronique Ferchaud-Roucher; Maud Chétiveaux; Yassine Zaïr; Khadija Ouguerram; Michel Krempf; Estelle Nobécourt
Journal:  J Lipid Res       Date:  2016-01-15       Impact factor: 5.922

Review 10.  Lipoprotein (a): When to Measure and How to Treat?

Authors:  David Rhainds; Mathieu R Brodeur; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2021-07-08       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.